[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495270":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":21,"locations":30,"responsibleParty":51,"collaborators":55,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":10,"enrollmentInfo":84,"targetDuration":10,"studyType":87,"phases":10,"briefSummary":88,"conditions":89,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",[8,12,15,18],{"label":9,"type":10,"description":11,"interventionNames":10},"Group 1",null,"\"standard\": only routine diagnostic procedures are performed",{"label":13,"type":10,"description":14,"interventionNames":10},"Group 2A","\"less invasive\": in addition to routine monitoring, patients also undergo semen sampling",{"label":16,"type":10,"description":17,"interventionNames":10},"Group 2B","\"less invasive\": in addition to routine monitoring, patients undergo semen sampling and\u002For leukapheresis.",{"label":19,"type":10,"description":20,"interventionNames":10},"Group 3","\"extended\": patients undergo (in addition to routine sampling) semen sampling, invasive tissue sampling (GALT and\u002For lumbar puncture) and leukapheresis.",[22,27],{"name":23,"role":24,"phone":25,"phoneExt":10,"email":26},"Pien van Paassen, MD","CONTACT","0031642970500","p.vanpaassen@amsterdamumc.nl",{"name":28,"role":24,"phone":10,"phoneExt":10,"email":29},"Godelieve de Bree, MD PhD","g.j.debree@amsterdamumc.nl",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Amsterdam UMC, location AMC","RECRUITING","Amsterdam","North Holland","1105 AZ","Netherlands","NL",{"type":40,"coordinates":41},"Point",[42,43],4.88969,52.37403,{"lat":43,"lon":42},[46,48],{"name":23,"role":24,"phone":47,"phoneExt":10,"email":26},"003142970500",{"name":49,"role":24,"phone":10,"phoneExt":10,"email":50},"Frank Pijnappel","f.j.pijnappel@amsterdamumc.nl",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Prof. Jan Prins","Full professor",[56,58,60,62,64,66,68,71,73],{"name":57,"class":6},"UMC Utrecht",{"name":59,"class":6},"Rijnstate Hospital",{"name":61,"class":6},"Erasmus Medical Center",{"name":63,"class":6},"Onze Lieve Vrouwe Gasthuis",{"name":65,"class":6},"Radboud University Medical Center",{"name":67,"class":6},"Maasstad Hospital",{"name":69,"class":70},"DC Clinics","UNKNOWN",{"name":72,"class":6},"Amsterdam UMC, location VUmc",{"name":74,"class":6},"Leiden University Medical Center","100495270","netherlands-cohort-study-on-acute-hiv-infection-100495270",false,"NCT05728996","Netherlands Cohort Study on Acute HIV Infection","NOVA","Inclusion Criteria:\n\n* Written informed consent to store samples and perform genetic testing.\n* Separate written informed consent for invasive sampling procedures: leukapheresis, sigmoidoscopy with biopsies, lymph node excision biopsy and lumbar puncture, with storage of samples.\n* Age \\>= 18 years\n* An acute HIV-1 infection, defined according to the Fiebig stages I-IV (acute infection), as described in the previous paragraph (HIV-1 RNA positive and 4th generation ELISA negative or HIV-1 RNA positive and 4th generation HIV ELISA positive with indeterminate Western Blot). Patients in Fiebig stage V and VI (recent infection) will only be included if they have a documented negative HIV test 6 months prior to the positive test or if they are in Fiebig stage V with a p31 negative blot\n* Female subjects should be willing to use adequate contraception.\n\nExclusion Criteria:\n\n* Contraindication for proposed cART regimen (e.g. impaired renal function).\n* Mental disorder that in the view of the investigator would interfere with adherence to the treatment or the study procedures, or the decision to participate in the study.\n* Immunosuppressive medication or other diseases associated with immunodeficiency.","ALL","18 Years",{"count":85,"type":86},183,"ESTIMATED","OBSERVATIONAL","Investigation of the size, variability and localization of the (pro) viral reservoir and the properties of HIV-specific immune response related to \"post-treatment viral remission' achievement and \u002F or duration. In addition we will study the factors that determine latency in the different host cells, their sensitivity to induction of replication competent virus by various agents and the potential application of these agents in \"post-treatment viral remission\".\n\nThis all will be studied in patients included during acute phase of the infection who start antiretroviral therapy immediately upon diagnosis.",[90],"Acute HIV Infection","2023-02-06",{"date":93,"type":94},"2023-02-15","ACTUAL",{"date":96,"type":94},"2015-08-01",{"date":98,"type":86},"2028-08-01",{"name":53,"class":6},1]